Safety and Benefit of Discontinuing Statin Therapy in the Setting of Advanced, Life-Limiting Illness
- 1 May 2015
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 175 (5), 691-700
- https://doi.org/10.1001/jamainternmed.2015.0289
Abstract
Safe and effective use of medicines includes medication selection and dosing for a targeted indication, monitoring for benefits and harms, and discontinuation when appropriate. Data from clinical trials guide the initiation of long-term medication therapy for primary or secondary prevention of cardiovascular disease but rarely define the timing, safety, or risks of discontinuing the agents. As a result, the number of medications often accumulates.1,2Keywords
This publication has 46 references indexed in Scilit:
- Rationalizing Prescribing for Older Patients with Multimorbidity: Considering Time to BenefitDrugs & Aging, 2013
- Effect of Statins on Skeletal Muscle FunctionCirculation, 2013
- Palliative Medicine and Decision Science: The Critical Need for a Shared Agenda To Foster Informed Patient Choice in Serious IllnessJournal of Palliative Medicine, 2011
- The effects of statins on skeletal muscle strength and exercise performanceCurrent Opinion in Lipidology, 2010
- Discontinuing Medications: A Novel Approach for Revising the Prescribing Stage of the Medication‐Use ProcessJournal of the American Geriatrics Society, 2008
- Statins in the Last Six Months of Life: A Recognizable, Life-Limiting Condition Does Not Decrease their UseJournal of Palliative Medicine, 2008
- Rosuvastatin in Older Patients with Systolic Heart FailureThe New England Journal of Medicine, 2007
- An Assessment of Statin Safety by Muscle ExpertsThe American Journal of Cardiology, 2006
- Managing comorbidities in patients at the end of lifeBMJ, 2004
- Shared decision-making in the medical encounter: What does it mean? (or it takes at least two to tango)Social Science & Medicine (1982), 1997